Reig Jofre and Leanbio create the joint venture Syna Therapeutics for the development of biosimilar products

Friday, 23 March 2018.

  • Syna Therapeutics will devote to the development of biopharmaceutical products in the field of biosimilar and innovative molecules
  • Thanks to this strategic alliance, Reig Jofre will expand its development portfolio of high added value injectable products, targeting a world market of around €1,000 M

The pharmaceutical company Reig Jofre strengthens its commitment to open innovation and the development of injectable and freeze-dried products with the creation of the joint venture Syna Therapeutics, for the development of biopharmaceutical products in the field of biosimilar products and innovative molecules for a world market of around 1,000 million euros.

The new alliance is 50% owned by LeanBio, a biotechnology company founded by Dr. Andreu Soldevila in 2014, specialized in the development of biological products for the pharmaceutical, biopharmaceutical and cosmetic sectors, and by Reig Jofre, who will provide its extensive expertise in the formulation, stabilization and pharmaceutical development of biological and injectable products.

Syna Therapeutics will be headed by Dr. Andreu Soldevila as CEO. Gabriel Roig, as the president of the Board of Directors, will also count on Isabel Amat and Rafael Montilla. The headquarters is located in the Barcelona Science Park (PCB).

Descargue el documento completo (PDF)

This site uses only technical third party cookies to provide better service, when browsing this website you agree to its use. See ourlegal advice. Agree

Our website is protected by DMC Firewall!